Format

Send to

Choose Destination
Cancer Invest. 2014 May;32(4):136-43. doi: 10.3109/07357907.2014.883528. Epub 2014 Feb 28.

Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.

Author information

1
1Departments of 1Biochemistry.

Abstract

Serum mass profiling can discern physiological changes associated with specific disease states and their progression. Sera (86 total) from control individuals and patients with stage I nonsmall cell lung cancer or benign small pulmonary nodules were discriminated retrospectively by serum changes discerned by mass profiling. Control individuals were distinguished from patients with Stage I lung cancer or benign nodules with test sensitivities of 89% and 83%. Lung cancer patients versus those with benign nodules were distinguished with 80% sensitivity. This study exhibits progress toward a minimally-invasive aid in early detection of lung cancer and monitoring small pulmonary nodules for malignancy.

PMID:
24579933
DOI:
10.3109/07357907.2014.883528
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center